{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 430668, "items": [{"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T04:41:40Z", "timestamp": 1574484100737}, "reference-count": 37, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 9, 1]], "date-time": "2012-09-01T00:00:00Z", "timestamp": 1346457600000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"name": "Helsinn Healthcare SA", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Peptides"], "published-print": {"date-parts": [[2012, 9]]}, "DOI": "10.1016/j.peptides.2012.06.010", "type": "journal-article", "created": {"date-parts": [[2012, 6, 23]], "date-time": "2012-06-23T03:46:45Z", "timestamp": 1340423205000}, "page": "86-97", "source": "Crossref", "is-referenced-by-count": 34, "title": ["In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant"], "prefix": "10.1016", "volume": "37", "author": [{"given": "Anna", "family": "Rizzi", "sequence": "first", "affiliation": []}, {"given": "Barbara", "family": "Campi", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Camarda", "sequence": "additional", "affiliation": []}, {"given": "Stefano", "family": "Molinari", "sequence": "additional", "affiliation": []}, {"given": "Sergio", "family": "Cantoreggi", "sequence": "additional", "affiliation": []}, {"given": "Domenico", "family": "Regoli", "sequence": "additional", "affiliation": []}, {"given": "Claudio", "family": "Pietra", "sequence": "additional", "affiliation": []}, {"given": "Girolamo", "family": "Calo\u2019", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Peptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0196978112002720?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0196978112002720?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 22]], "date-time": "2018-11-22T15:53:41Z", "timestamp": 1542902021000}, "score": 50.841084, "issued": {"date-parts": [[2012, 9]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[2012, 9]]}, "issue": "1"}, "alternative-id": ["S0196978112002720"], "URL": "http://dx.doi.org/10.1016/j.peptides.2012.06.010", "ISSN": ["0196-9781"], "issn-type": [{"value": "0196-9781", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T11:03:41Z", "timestamp": 1574593421758}, "reference-count": 27, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 7, 1]], "date-time": "2015-07-01T00:00:00Z", "timestamp": 1435708800000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"name": "Helsinn Healthcare SA", "award": []}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Peptides"], "published-print": {"date-parts": [[2015, 7]]}, "DOI": "10.1016/j.peptides.2015.03.021", "type": "journal-article", "created": {"date-parts": [[2015, 4, 6]], "date-time": "2015-04-06T03:53:29Z", "timestamp": 1428292409000}, "page": "26-32", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 5, "title": ["In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant"], "prefix": "10.1016", "volume": "69", "author": [{"given": "Chiara", "family": "Ruzza", "sequence": "first", "affiliation": []}, {"given": "Anna", "family": "Rizzi", "sequence": "additional", "affiliation": []}, {"given": "Davide", "family": "Malfacini", "sequence": "additional", "affiliation": []}, {"given": "Stefano", "family": "Molinari", "sequence": "additional", "affiliation": []}, {"given": "Claudio", "family": "Giuliano", "sequence": "additional", "affiliation": []}, {"given": "Emanuela", "family": "Lovati", "sequence": "additional", "affiliation": []}, {"given": "Claudio", "family": "Pietra", "sequence": "additional", "affiliation": []}, {"given": "Girolamo", "family": "Calo\u2019", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Peptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0196978115000881?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0196978115000881?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 23]], "date-time": "2018-09-23T21:51:02Z", "timestamp": 1537739462000}, "score": 43.03629, "issued": {"date-parts": [[2015, 7]]}, "references-count": 27, "alternative-id": ["S0196978115000881"], "URL": "http://dx.doi.org/10.1016/j.peptides.2015.03.021", "ISSN": ["0196-9781"], "issn-type": [{"value": "0196-9781", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant", "name": "articletitle", "label": "Article Title"}, {"value": "Peptides", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.peptides.2015.03.021", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2015 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T03:25:16Z", "timestamp": 1575257116191}, "reference-count": 35, "publisher": "Elsevier BV", "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Peptides"], "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1016/j.peptides.2013.07.018", "type": "journal-article", "created": {"date-parts": [[2013, 7, 30]], "date-time": "2013-07-30T16:17:07Z", "timestamp": 1375201027000}, "page": "27-35", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 5, "title": ["In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1"], "prefix": "10.1016", "volume": "48", "author": [{"given": "V.", "family": "Camarda", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Ruzza", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Rizzi", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Trapella", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Guerrini", "sequence": "additional", "affiliation": []}, {"given": "R.K.", "family": "Reinscheid", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Calo", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Peptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0196978113002581?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0196978113002581?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 14]], "date-time": "2018-10-14T07:58:03Z", "timestamp": 1539503883000}, "score": 39.005566, "issued": {"date-parts": [[2013, 10]]}, "references-count": 35, "alternative-id": ["S0196978113002581"], "URL": "http://dx.doi.org/10.1016/j.peptides.2013.07.018", "ISSN": ["0196-9781"], "issn-type": [{"value": "0196-9781", "type": "print"}], "subject": ["Biochemistry", "Physiology", "Endocrinology", "Cellular and Molecular Neuroscience"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1", "name": "articletitle", "label": "Article Title"}, {"value": "Peptides", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.peptides.2013.07.018", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T07:02:38Z", "timestamp": 1575097358950}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 1, 1]], "date-time": "1995-01-01T00:00:00Z", "timestamp": 788918400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacological Research"], "published-print": {"date-parts": [[1995, 1]]}, "DOI": "10.1016/1043-6618(95)87066-0", "type": "journal-article", "created": {"date-parts": [[2003, 10, 11]], "date-time": "2003-10-11T09:00:14Z", "timestamp": 1065862814000}, "page": "202", "source": "Crossref", "is-referenced-by-count": 0, "title": ["In vitro pharmacology of SCH 58261, a new potent and selective A2a adenosine receptor antagonist"], "prefix": "10.1016", "volume": "31", "author": [{"given": "C.", "family": "Zocchi", "sequence": "first", "affiliation": []}, {"given": "E.", "family": "Ongini", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Conti", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Ferrara", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Negretti", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Dionisotti", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacological Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:1043661895870660?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:1043661895870660?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 20]], "date-time": "2019-02-20T19:25:51Z", "timestamp": 1550690751000}, "score": 34.089294, "issued": {"date-parts": [[1995, 1]]}, "references-count": 0, "alternative-id": ["1043661895870660"], "URL": "http://dx.doi.org/10.1016/1043-6618(95)87066-0", "ISSN": ["1043-6618"], "issn-type": [{"value": "1043-6618", "type": "print"}], "subject": ["Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:40:37Z", "timestamp": 1574113237136}, "reference-count": 4, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1994, 5, 1]], "date-time": "1994-05-01T00:00:00Z", "timestamp": 767750400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacological Research"], "published-print": {"date-parts": [[1994, 5]]}, "DOI": "10.1016/1043-6618(94)80077-4", "type": "journal-article", "created": {"date-parts": [[2004, 2, 21]], "date-time": "2004-02-21T10:23:26Z", "timestamp": 1077359006000}, "page": "402", "source": "Crossref", "is-referenced-by-count": 1, "title": ["BIMU 1, a 5HT3-receptor antagonist and 5HT4-receptor agonist, accelerates the gastric emptying of liquids in the conscious dog"], "prefix": "10.1016", "volume": "29", "author": [{"given": "Carlo A.", "family": "Rizzi", "sequence": "first", "affiliation": []}, {"given": "Angelo", "family": "Sagrada", "sequence": "additional", "affiliation": []}, {"given": "Pieerino", "family": "Schiantarelli", "sequence": "additional", "affiliation": []}, {"given": "Arturo", "family": "Donetti", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacological Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:1043661894800774?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:1043661894800774?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 15]], "date-time": "2019-02-15T01:54:27Z", "timestamp": 1550195667000}, "score": 33.527374, "issued": {"date-parts": [[1994, 5]]}, "references-count": 4, "journal-issue": {"published-print": {"date-parts": [[1994, 5]]}, "issue": "4"}, "alternative-id": ["1043661894800774"], "URL": "http://dx.doi.org/10.1016/1043-6618(94)80077-4", "ISSN": ["1043-6618"], "issn-type": [{"value": "1043-6618", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T07:02:58Z", "timestamp": 1575097378817}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 1, 1]], "date-time": "1995-01-01T00:00:00Z", "timestamp": 788918400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacological Research"], "published-print": {"date-parts": [[1995]]}, "DOI": "10.1016/1043-6618(95)87342-2", "type": "journal-article", "created": {"date-parts": [[2003, 10, 11]], "date-time": "2003-10-11T09:00:14Z", "timestamp": 1065862814000}, "page": "271-271", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Feeding in rats induced by non-selective 5-HT receptor antagonists is attenuated by a selective 5-HT1A receptor antagonist"], "prefix": "10.1016", "volume": "31", "author": [{"given": "J", "family": "HARTLEY", "sequence": "first", "affiliation": []}, {"given": "G", "family": "BROWN", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "FLETCHER", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacological Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:1043661895873422?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:1043661895873422?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 20]], "date-time": "2019-02-20T19:22:09Z", "timestamp": 1550690529000}, "score": 33.295437, "issued": {"date-parts": [[1995]]}, "references-count": 0, "alternative-id": ["1043661895873422"], "URL": "http://dx.doi.org/10.1016/1043-6618(95)87342-2", "ISSN": ["1043-6618"], "issn-type": [{"value": "1043-6618", "type": "print"}], "subject": ["Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T07:02:39Z", "timestamp": 1575097359346}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 1, 1]], "date-time": "1995-01-01T00:00:00Z", "timestamp": 788918400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacological Research"], "published-print": {"date-parts": [[1995, 1]]}, "DOI": "10.1016/1043-6618(95)87042-3", "type": "journal-article", "created": {"date-parts": [[2003, 10, 11]], "date-time": "2003-10-11T09:00:14Z", "timestamp": 1065862814000}, "page": "196", "source": "Crossref", "is-referenced-by-count": 0, "title": ["IRFI 117: A novel highly selective xanthine A1-Adenosine antagonist"], "prefix": "10.1016", "volume": "31", "author": [{"given": "A.", "family": "D'Alessandro", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Altobelli", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Ceccarelli", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Paesano", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacological Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:1043661895870423?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:1043661895870423?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 20]], "date-time": "2019-02-20T19:26:15Z", "timestamp": 1550690775000}, "score": 32.769245, "issued": {"date-parts": [[1995, 1]]}, "references-count": 0, "alternative-id": ["1043661895870423"], "URL": "http://dx.doi.org/10.1016/1043-6618(95)87042-3", "ISSN": ["1043-6618"], "issn-type": [{"value": "1043-6618", "type": "print"}], "subject": ["Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T08:46:33Z", "timestamp": 1574153193264}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1992, 9, 1]], "date-time": "1992-09-01T00:00:00Z", "timestamp": 715305600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Regulatory Peptides"], "published-print": {"date-parts": [[1992, 9]]}, "DOI": "10.1016/0167-0115(92)90918-k", "type": "journal-article", "created": {"date-parts": [[2003, 2, 12]], "date-time": "2003-02-12T15:11:46Z", "timestamp": 1045062706000}, "page": "S63", "source": "Crossref", "is-referenced-by-count": 0, "title": ["In vivo and in vitro pharmacology of SR48,968 as tachykinin NK-2 receptor antagonist"], "prefix": "10.1016", "volume": "37", "author": [{"given": "S.", "family": "Giuliani", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Patacchini", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Giachetti", "sequence": "additional", "affiliation": []}, {"given": "C.A.", "family": "Maggi", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Regulatory Peptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:016701159290918K?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:016701159290918K?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 27]], "date-time": "2019-03-27T18:51:38Z", "timestamp": 1553712698000}, "score": 32.410545, "issued": {"date-parts": [[1992, 9]]}, "references-count": 0, "alternative-id": ["016701159290918K"], "URL": "http://dx.doi.org/10.1016/0167-0115(92)90918-k", "ISSN": ["0167-0115"], "issn-type": [{"value": "0167-0115", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T20:04:48Z", "timestamp": 1575317088198}, "reference-count": 32, "publisher": "American Society for Pharmacology & Experimental Therapeutics (ASPET)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J Pharmacol Exp Ther"], "published-print": {"date-parts": [[2009, 2]]}, "DOI": "10.1124/jpet.108.143867", "type": "journal-article", "created": {"date-parts": [[2008, 10, 30]], "date-time": "2008-10-30T01:35:54Z", "timestamp": 1225330554000}, "page": "549-555", "source": "Crossref", "is-referenced-by-count": 47, "title": ["In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S"], "prefix": "10.1124", "volume": "328", "author": [{"given": "Valeria", "family": "Camarda", "sequence": "first", "affiliation": []}, {"given": "Anna", "family": "Rizzi", "sequence": "additional", "affiliation": []}, {"given": "Chiara", "family": "Ruzza", "sequence": "additional", "affiliation": []}, {"given": "Silvia", "family": "Zucchini", "sequence": "additional", "affiliation": []}, {"given": "Giuliano", "family": "Marzola", "sequence": "additional", "affiliation": []}, {"given": "Erika", "family": "Marzola", "sequence": "additional", "affiliation": []}, {"given": "Remo", "family": "Guerrini", "sequence": "additional", "affiliation": []}, {"given": "Severo", "family": "Salvadori", "sequence": "additional", "affiliation": []}, {"given": "Rainer K.", "family": "Reinscheid", "sequence": "additional", "affiliation": []}, {"given": "Domenico", "family": "Regoli", "sequence": "additional", "affiliation": []}, {"given": "Girolamo", "family": "Cal\u00f2", "sequence": "additional", "affiliation": []}], "member": "36", "published-online": {"date-parts": [[2008, 10, 29]]}, "reference": [{"key": "2019081411540561000_328.2.549.1", "volume": "32", "first-page": "458.1/CC11", "year": "2006", "journal-title": "Soc Neurosci Abstr"}, {"key": "2019081411540561000_328.2.549.2", "DOI": "10.1152/ajplung.00174.2006", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.3", "DOI": "10.1016/j.bbrc.2005.05.029", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.4", "DOI": "10.1074/jbc.M603691200", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.5", "volume": "9", "first-page": "551", "year": "2006", "journal-title": "Curr Opin Drug Discov Dev"}, {"key": "2019081411540561000_328.2.549.6", "DOI": "10.1038/nm1544", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.7", "volume": "32", "first-page": "726.18/D56", "year": "2006", "journal-title": "Soc Neurosci Abstr"}, {"key": "2019081411540561000_328.2.549.8", "DOI": "10.1021/jm701204n", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.9", "volume": "32", "first-page": "809.7/O15", "year": "2006", "journal-title": "Soc Neurosci Abstr"}, {"key": "2019081411540561000_328.2.549.10", "DOI": "10.1006/abio.1999.4061", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.11", "DOI": "10.1016/j.neuron.2008.07.002", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.12", "DOI": "10.1073/pnas.0707146105", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.13", "unstructured": "Kenakin T (2004) A Pharmacology Primer, Elsevier Academic Press, San Diego, CA."}, {"key": "2019081411540561000_328.2.549.14", "DOI": "10.1016/S0306-4522(03)00554-2", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.15", "DOI": "10.1126/science.1090010", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.16", "DOI": "10.1016/0160-5402(86)90038-0", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.17", "DOI": "10.1007/s00213-008-1080-4", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.18", "DOI": "10.1124/pr.55.4.4", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.19", "DOI": "10.1385/ENDO:30:1:75", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.20", "DOI": "10.1124/jpet.107.135103", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.21", "unstructured": "Raiteri L, Luccini E, Romei C, and Salvadori S (2008) Neuropeptide s modulates neurotransmitter release from mouse frontal cortex nerve terminals, in Europen Opioid Conference with European Neuropeptide Club Joint Meeting; 8\u201311 April 2008; Ferrara, Italy. p 50."}, {"key": "2019081411540561000_328.2.549.22", "DOI": "10.1016/j.peptides.2007.01.008", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.23", "DOI": "10.1124/jpet.105.093427", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.24", "DOI": "10.1007/s002100000358", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.25", "DOI": "10.1038/bjp.2008.96", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.26", "DOI": "10.1074/jbc.M601846200", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.27", "unstructured": "Schild HO (1973) Receptor classification with special reference to beta adrenergic receptors, in Drug receptors pp 29-36, University Park Press, Baltimore, MD.", "DOI": "10.1007/978-1-349-00910-7_3", "doi-asserted-by": "crossref"}, {"key": "2019081411540561000_328.2.549.28", "DOI": "10.1210/en.2005-1280", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.29", "DOI": "10.1021/jm0706822", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.30", "DOI": "10.1016/j.peptides.2008.08.014", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.31", "DOI": "10.1002/cne.21159", "doi-asserted-by": "publisher"}, {"key": "2019081411540561000_328.2.549.32", "DOI": "10.1016/j.neuron.2004.08.005", "doi-asserted-by": "publisher"}], "container-title": ["Journal of Pharmacology and Experimental Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1124/jpet.108.143867", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 14]], "date-time": "2019-08-14T19:04:48Z", "timestamp": 1565809488000}, "score": 31.10564, "issued": {"date-parts": [[2008, 10, 29]]}, "references-count": 32, "journal-issue": {"published-online": {"date-parts": [[2009, 1, 21]]}, "published-print": {"date-parts": [[2009, 2]]}, "issue": "2"}, "alternative-id": ["10.1124/jpet.108.143867"], "URL": "http://dx.doi.org/10.1124/jpet.108.143867", "relation": {"cites": []}, "ISSN": ["0022-3565", "1521-0103"], "issn-type": [{"value": "0022-3565", "type": "print"}, {"value": "1521-0103", "type": "electronic"}], "subject": ["Molecular Medicine", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T17:00:01Z", "timestamp": 1574096401428}, "reference-count": 37, "publisher": "Elsevier BV", "issue": "1-2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 11, 1]], "date-time": "1995-11-01T00:00:00Z", "timestamp": 815184000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Brain Research"], "published-print": {"date-parts": [[1995, 11]]}, "DOI": "10.1016/0006-8993(95)00940-r", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T13:49:34Z", "timestamp": 1027604974000}, "page": "115-120", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist"], "prefix": "10.1016", "volume": "700", "author": [{"given": "A. Jon", "family": "Stoessl", "sequence": "first", "affiliation": []}, {"given": "Muriel", "family": "Brackstone", "sequence": "additional", "affiliation": []}, {"given": "Nagalingham", "family": "Rajakumar", "sequence": "additional", "affiliation": []}, {"given": "Candace J.", "family": "Gibson", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Brain Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:000689939500940R?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:000689939500940R?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 29]], "date-time": "2019-04-29T01:56:47Z", "timestamp": 1556503007000}, "score": 31.095543, "issued": {"date-parts": [[1995, 11]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[1995, 11]]}, "issue": "1-2"}, "alternative-id": ["000689939500940R"], "URL": "http://dx.doi.org/10.1016/0006-8993(95)00940-r", "ISSN": ["0006-8993"], "issn-type": [{"value": "0006-8993", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T23:35:18Z", "timestamp": 1574120118376}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1994, 4, 1]], "date-time": "1994-04-01T00:00:00Z", "timestamp": 765158400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Neuropeptides"], "published-print": {"date-parts": [[1994, 4]]}, "DOI": "10.1016/0143-4179(94)90219-4", "type": "journal-article", "created": {"date-parts": [[2004, 4, 19]], "date-time": "2004-04-19T07:26:56Z", "timestamp": 1082359616000}, "page": "35", "source": "Crossref", "is-referenced-by-count": 8, "title": ["In vivo pharmacological properties of RPR100893, a novel non-peptide antagonist of the human NK1 receptor"], "prefix": "10.1016", "volume": "26", "author": [{"given": "S.M.", "family": "Moussaoui", "sequence": "first", "affiliation": []}, {"given": "F.", "family": "Montier", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Carruette", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Fardin", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Floch", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Garret", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Neuropeptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:0143417994902194?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:0143417994902194?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 12]], "date-time": "2019-02-12T01:24:39Z", "timestamp": 1549934679000}, "score": 30.734636, "issued": {"date-parts": [[1994, 4]]}, "references-count": 0, "alternative-id": ["0143417994902194"], "URL": "http://dx.doi.org/10.1016/0143-4179(94)90219-4", "ISSN": ["0143-4179"], "issn-type": [{"value": "0143-4179", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:49:59Z", "timestamp": 1574416199165}, "reference-count": 43, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2006, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 5]]}, "DOI": "10.1111/j.1476-5381.2010.00730.x", "type": "journal-article", "created": {"date-parts": [[2010, 3, 5]], "date-time": "2010-03-05T19:16:30Z", "timestamp": 1267816590000}, "page": "399-409", "source": "Crossref", "is-referenced-by-count": 46, "title": ["Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor"], "prefix": "10.1111", "volume": "160", "author": [{"given": "F", "family": "Wunder", "sequence": "first", "affiliation": []}, {"given": "H", "family": "Tinel", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Kast", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Geerts", "sequence": "additional", "affiliation": []}, {"given": "EM", "family": "Becker", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Kolkhof", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "H\u00fctter", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Erg\u00fcden", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "H\u00e4rter", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 3, 5]]}, "reference": [{"issue": "1", "key": "10.1111/j.1476-5381.2010.00730.x-BIB1|cit1", "first-page": "S1", "article-title": "Guide to receptors and channels (GRAC), 4th edition (2009 revision)", "volume": "158", "author": "Alexander", "year": "2009", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB2|cit2", "first-page": "47", "article-title": "Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4", "volume": "4", "author": "Allen", "year": "1993", "journal-title": "Cardioscience"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "2406", "DOI": "10.1161/01.CIR.97.24.2406", "article-title": "Differential leukotriene constrictor responses in human atherosclerotic coronary arteries", "volume": "97", "author": "Allen", "year": "1998", "journal-title": "Circulation"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1007/s10557-008-6140-9", "article-title": "Leukotriene signaling in atherosclerosis and ischemia", "volume": "23", "author": "B\u00e4ck", "year": "2009", "journal-title": "Cardiovasc Drugs Ther"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "46129", "DOI": "10.1074/jbc.M407057200", "article-title": "Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice", "volume": "279", "author": "Beller", "year": "2004", "journal-title": "J Biol Chem"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB6|cit6", "first-page": "235", "article-title": "Leukotrienes C4, D4 and E4: effects on human and guinea pig cardiac preparations in vitro", "volume": "221", "author": "Burke", "year": "1982", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "469", "DOI": "10.1002/med.20071", "article-title": "Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends", "volume": "27", "author": "Capra", "year": "2007", "journal-title": "Med Res Rev"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "230", "DOI": "10.1161/01.CIR.85.1.230", "article-title": "Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation", "volume": "85", "author": "Carry", "year": "1992", "journal-title": "Circulation"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "4615", "DOI": "10.1038/sj.emboj.7601341", "article-title": "The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor", "volume": "25", "author": "Ciana", "year": "2006", "journal-title": "EMBO J"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB10|cit10", "first-page": "283", "article-title": "Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature", "volume": "23", "author": "Coleman", "year": "1995", "journal-title": "Adv Prostaglandin Thromboxane Leukot Res"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1056/NEJM199901213400306", "article-title": "Treatment of asthma with drugs modifying the leukotriene pathway", "volume": "340", "author": "Drazen", "year": "1999", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "499", "DOI": "10.1007/BF01865508", "article-title": "Cardiovascular effects of leukotrienes", "volume": "3", "author": "Fauler", "year": "1989", "journal-title": "Cardiovasc Drugs Ther"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "S112", "DOI": "10.1164/ajrccm.161.supplement_1.ltta-22", "article-title": "Leukotrienes in cardiovascular diseases", "volume": "161", "author": "Folco", "year": "2000", "journal-title": "Am J Respir Crit Care Med"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/0922-4106(93)90149-4", "article-title": "Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung", "volume": "244", "author": "Frey", "year": "1993", "journal-title": "Eur J Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "1871", "DOI": "10.1126/science.294.5548.1871", "article-title": "Prostaglandins and leukotrienes: advances in eicosanoid biology", "volume": "294", "author": "Funk", "year": "2001", "journal-title": "Science"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "664", "DOI": "10.1038/nrd1796", "article-title": "Leukotriene modifiers as potential therapeutics for cardiovascular disease", "volume": "4", "author": "Funk", "year": "2005", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB17|cit17", "unstructured": "H\u00e4rter M Erg\u00fcden J Wunder F Tinel H K\u00f6bberling J Becker EM et\u2003al 2004 Isophthalic acid derivatives"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "30531", "DOI": "10.1074/jbc.M003490200", "article-title": "Characterization of the human cysteinyl leukotriene 2 receptor", "volume": "275", "author": "Heise", "year": "2000", "journal-title": "J Biol Chem"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1038/ng1311", "article-title": "The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke", "volume": "36", "author": "Helgadottir", "year": "2004", "journal-title": "Nat Genet"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB21|cit20", "doi-asserted-by": "crossref", "first-page": "3360", "DOI": "10.1161/01.CIR.0000147775.50954.AA", "article-title": "Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure", "volume": "110", "author": "Hui", "year": "2004", "journal-title": "Circulation"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB20|cit21", "doi-asserted-by": "crossref", "first-page": "47489", "DOI": "10.1074/jbc.M107556200", "article-title": "The murine cysteinyl leukotriene 2 (CysLT2) receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization", "volume": "276", "author": "Hui", "year": "2001", "journal-title": "J Biol Chem"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "592", "DOI": "10.2353/ajpath.2008.070834", "article-title": "Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury", "volume": "172", "author": "Jiang", "year": "2008", "journal-title": "Am J Pathol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "1088", "DOI": "10.1006/bbrc.2001.5695", "article-title": "Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells", "volume": "287", "author": "Kamohara", "year": "2001", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "1503", "DOI": "10.4049/jimmunol.173.3.1503", "article-title": "Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses", "volume": "173", "author": "Kanaoka", "year": "2004", "journal-title": "J Immunol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "978", "DOI": "10.1164/ajrccm/141.4_Pt_1.978", "article-title": "The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist", "volume": "141", "author": "Krell", "year": "1990", "journal-title": "Am Rev Respir Dis"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB26|cit26", "first-page": "800", "article-title": "A second cysteinyl leukotriene receptor in human lung", "volume": "263", "author": "Labat", "year": "1992", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB28|cit27", "first-page": "101", "article-title": "Leukotrienes: role in cardiovascular physiology", "volume": "18", "author": "Letts", "year": "1987", "journal-title": "Cardiovasc Clin"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB27|cit28", "doi-asserted-by": "crossref", "first-page": "169", "DOI": "10.1111/j.1476-5381.1982.tb09203.x", "article-title": "The actions of leukotrienes C4 and D4 on guinea-pig isolated hearts", "volume": "76", "author": "Letts", "year": "1982", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "789", "DOI": "10.1038/21658", "article-title": "Characterization of the human cysteinyl leukotriene CysLT1 receptor", "volume": "399", "author": "Lynch", "year": "1999", "journal-title": "Nature"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB31|cit30", "doi-asserted-by": "crossref", "first-page": "11685", "DOI": "10.1073/pnas.0905364106", "article-title": "GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4", "volume": "106", "author": "Maekawa", "year": "2009", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB30|cit31", "doi-asserted-by": "crossref", "first-page": "16695", "DOI": "10.1073/pnas.0808993105", "article-title": "Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors", "volume": "105", "author": "Maekawa", "year": "2008", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1016/0090-6980(91)90008-4", "article-title": "Effect of ICI 198,615, SK+F 104,353, MK-571 and CGP45715A on cysteinyl leukotriene-induced responses in guinea-pig heart", "volume": "41", "author": "McLeod", "year": "1991", "journal-title": "Prostaglandins"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "4352", "DOI": "10.1096/fj.08-113274", "article-title": "Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport", "volume": "22", "author": "Moos", "year": "2008", "journal-title": "FASEB J"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "1601", "DOI": "10.1124/mol.58.6.1601", "article-title": "Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist", "volume": "58", "author": "Nothacker", "year": "2000", "journal-title": "Mol Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "18763", "DOI": "10.1074/jbc.M109447200", "article-title": "Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution", "volume": "277", "author": "Ogasawara", "year": "2002", "journal-title": "J Biol Chem"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "1966", "DOI": "10.2174/092986707781368522", "article-title": "Antileukotriene drugs: clinical application, effectiveness and safety", "volume": "14", "author": "Riccioni", "year": "2007", "journal-title": "Curr Med Chem"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "657", "DOI": "10.1124/mol.56.3.657", "article-title": "Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor", "volume": "56", "author": "Sarau", "year": "1999", "journal-title": "Mol Pharmacol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1007/s10787-006-1496-6", "article-title": "The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?", "volume": "14", "author": "Sharma", "year": "2006", "journal-title": "Inflammopharmacology"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "e37", "DOI": "10.1161/01.ATV.0000082689.46538.DF", "article-title": "Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells", "volume": "23", "author": "Sj\u00f6str\u00f6m", "year": "2003", "journal-title": "Arterioscler Thromb Vasc Biol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "1238", "DOI": "10.1073/pnas.242716099", "article-title": "Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis", "volume": "100", "author": "Spanbroek", "year": "2003", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "316", "DOI": "10.1006/bbrc.2000.3140", "article-title": "The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor", "volume": "274", "author": "Takasaki", "year": "2000", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "198", "DOI": "10.1002/clc.4960190312", "article-title": "Change of plasma leukotriene C4 during myocardial ischemia in humans", "volume": "19", "author": "Takase", "year": "1996", "journal-title": "Clin Cardiol"}, {"key": "10.1111/j.1476-5381.2010.00730.x-BIB43|cit43", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1016/0014-2999(94)00485-4", "article-title": "BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes", "volume": "264", "author": "Tudhope", "year": "1994", "journal-title": "Eur J Pharmacol"}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1476-5381.2010.00730.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 26]], "date-time": "2019-05-26T17:28:41Z", "timestamp": 1558891721000}, "score": 30.437643, "subtitle": ["Characterization of a CysLT2 receptor antagonist"], "issued": {"date-parts": [[2010, 3, 5]]}, "references-count": 43, "journal-issue": {"published-print": {"date-parts": [[2010, 5]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1111/j.1476-5381.2010.00730.x", "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:22:38Z", "timestamp": 1574490158487}, "reference-count": 38, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 7548, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1995, 1]]}, "DOI": "10.1111/j.1476-5381.1995.tb13241.x", "type": "journal-article", "created": {"date-parts": [[2012, 7, 19]], "date-time": "2012-07-19T22:54:38Z", "timestamp": 1342738478000}, "page": "405-413", "source": "Crossref", "is-referenced-by-count": 16, "title": ["In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670"], "prefix": "10.1111", "volume": "114", "author": [{"given": "Stephen A.", "family": "Douglas", "sequence": "first", "affiliation": []}, {"given": "Richard M.", "family": "Edwards", "sequence": "additional", "affiliation": []}, {"given": "John D.", "family": "Elliott", "sequence": "additional", "affiliation": []}, {"given": "Eliot H.", "family": "Ohlstein", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 7, 19]]}, "reference": [{"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "912", "DOI": "10.1111/j.1476-5381.1992.tb13385.x", "article-title": "Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15] endothelin-1 by BQ-123 in the anaesthetized rat", "volume": "107", "author": "BIGAUD", "year": "1992", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB2|cit2", "author": "BROOKS", "year": "1994", "article-title": "Nonpeptide endothelin receptor antagonists. III: effect of SB 209670 and BQ-123 on acute renal failure in anesthetized dogs", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "759", "DOI": "10.1038/365759a0", "article-title": "Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist", "volume": "365", "author": "CLOZEL", "year": "1993a", "journal-title": "Nature"}, {"issue": "Suppl. 8", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "S377", "DOI": "10.1097/00005344-199322008-00099", "article-title": "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology", "volume": "22", "author": "CLOZEL", "year": "1993b", "journal-title": "J. Cardiovasc. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "3301", "DOI": "10.1021/jm00095a029", "article-title": "Design of a functional antagonist of endothelin", "volume": "35", "author": "CODY", "year": "1992", "journal-title": "J. Med. Chem."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "9797", "DOI": "10.1073/pnas.85.24.9797", "article-title": "Pressor effects of circulating endothelin are limited by its removal from the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor", "volume": "85", "author": "NUCCI", "year": "1988", "journal-title": "Proc. Natl Acad. Sci. U.S.A."}, {"issue": "Suppl. 8", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "S98", "DOI": "10.1097/00005344-199322008-00027", "article-title": "In vitro and in vivo studies with a series of hexapeptide endothelin antagonists", "volume": "22", "author": "DOHERTY", "year": "1993", "journal-title": "J. Cardiovasc. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "315", "DOI": "10.1016/0014-2999(92)90718-J", "article-title": "Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses", "volume": "221", "author": "DOUGLAS", "year": "1992", "journal-title": "Eur. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB9|cit9", "first-page": "A42", "article-title": "SB 209670 inhibits the hemodynamic effects of endothelin-1 (ET-1) in the anesthetized rat", "volume": "8", "author": "DOUGLAS", "year": "1994a", "journal-title": "FASEB J."}, {"issue": "Suppl. 1", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB10|cit10", "first-page": "110", "article-title": "Pharmacological characterization of the nonpeptide endothelin receptor antagonist SB 209670", "volume": "72", "author": "DOUGLAS", "year": "1994b", "journal-title": "Can J. Physiol. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "561", "DOI": "10.1097/00004872-199405000-00009", "article-title": "BQ-123, a selective endothelin (ETA) receptor antagonist, lowers blood pressure in different rat models of hypertension", "volume": "12", "author": "DOUGLAS", "year": "1994c", "journal-title": "J. Hypertension"}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB12|cit12", "author": "DOUGLAS", "year": "1995", "article-title": "Antihypertensive actions of the novel, non-peptide endothelin receptor antagonist SB 209670", "journal-title": "Hypertension", "DOI": "10.1161/01.HYP.25.4.818", "doi-asserted-by": "crossref"}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "81", "DOI": "10.1111/j.1476-5381.1990.tb12093.x", "article-title": "Endothelium-dependent vascular activities of endothelin-like isopeptides in the isolated superior mesenteric arterial bed of the rat", "volume": "101", "author": "DOUGLAS", "year": "1990", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1111/j.1476-5381.1991.tb12428.x", "article-title": "Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat", "volume": "104", "author": "DOUGLAS", "year": "1991", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "190", "DOI": "10.1161/01.RES.75.1.190", "article-title": "A role for endogenous endothelin-1 in neointima formation following rat carotid artery balloon angioplasty: protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670", "volume": "75", "author": "DOUGLAS", "year": "1994d", "journal-title": "Circ. Res."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "81", "DOI": "10.1016/0014-2999(94)90085-X", "article-title": "Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction", "volume": "255", "author": "DOUGLAS", "year": "1994e", "journal-title": "Eur. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB17|cit17", "first-page": "A7", "article-title": "Antihypertensive effect of the endothelin receptor antagonist SB 209670 in conscious spontaneously hypertensive rats (SHR)", "volume": "8", "author": "ELLIOTT", "year": "1994a", "journal-title": "FASEB J."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "1553", "DOI": "10.1021/jm00037a003", "article-title": "(1S, 2R, 2S)-3-(2-carboxymethoxy-4-methoxyphenyl)-1-(3,4-methyl-enedioxy phenyl)-5-(prop-1-yloxy)indane-2-carboxylic acid, a potent and selective non-peptide endothelin receptor antagonist", "volume": "37", "author": "ELLIOTT", "year": "1994b", "journal-title": "J. Med. Chem."}, {"issue": "Suppl. 5", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "S202", "DOI": "10.1097/00005344-198900135-00057", "article-title": "Regional haemodynamic effects of endothelin-1 in conscious, unrestrained Wistar rats", "volume": "13", "author": "GARDINER", "year": "1989", "journal-title": "J. Cardiovasc. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "823", "DOI": "10.1111/j.1476-5381.1994.tb13153.x", "article-title": "Effects of bosentan (Ro 47-020), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats", "volume": "112", "author": "GARDINER", "year": "1994a", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "477", "DOI": "10.1111/j.1476-5381.1994.tb13098.x", "article-title": "Effects of an ETA-receptor antagonist, FR 139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats", "volume": "112", "author": "GARDINER", "year": "1994b", "journal-title": "Br. J. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "511", "DOI": "10.1111/j.1476-5381.1992.tb09009.x", "article-title": "Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery", "volume": "105", "author": "HARRISON", "year": "1992", "journal-title": "Br. J. Pharmacol."}, {"issue": "Suppl. 5", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "S197", "DOI": "10.1097/00005344-198900135-00055", "article-title": "Pressor effects of endothelin-1 and some analogs in the perfused superior mesenteric arterial bed of the rat", "volume": "13", "author": "HILEY", "year": "1989", "journal-title": "J. Cardiovasc. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "247", "DOI": "10.1016/0024-3205(92)90331-I", "article-title": "Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor", "volume": "50", "author": "IHARA", "year": "1991", "journal-title": "Life Sci."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB25|cit25", "first-page": "1024", "article-title": "Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration", "volume": "254", "author": "GOUVILLE", "year": "1990", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1016/0006-291X(92)91163-K", "article-title": "Venous smooth muscle contains vasoconstrictor ETB-like receptors", "volume": "184", "author": "MORELAND", "year": "1992", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB27|cit27", "author": "NAMBI", "year": "1994", "article-title": "Non-peptide endothelin receptor antagonists. I: effects on binding and signal transduction in human ETA and ETB receptors", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB28|cit28", "author": "OHLSTEIN", "year": "1994a", "article-title": "Non-peptide endothelin receptor antagonists. II: pharmacological characterization of SB 209670", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1002/ddr.430290207", "article-title": "Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology", "volume": "29", "author": "OHLSTEIN", "year": "1993", "journal-title": "Drug Develop. Res."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB30|cit30", "first-page": "595", "article-title": "The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism", "volume": "262", "author": "OHLSTEIN", "year": "1992", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB31|cit31", "first-page": "A803", "article-title": "SB 209670, a rationally designed potent non-peptide endothelin receptor antagonist", "volume": "8", "author": "OHLSTEIN", "year": "1994b", "journal-title": "FASEB J."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "8052", "DOI": "10.1073/pnas.91.17.8052", "article-title": "SB 209670, a rationally designed nonpeptide endothelin receptor agonist", "volume": "91", "author": "OHLSTEIN", "year": "1994c", "journal-title": "Proc. Natl Acad. Sci U.S.A."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "566", "DOI": "10.1016/0006-291X(92)90519-Q", "article-title": "Endothelin and structurally related analogs distinguish between endothelin receptor subtypes", "volume": "184", "author": "PANEK", "year": "1992", "journal-title": "Biochem. Biophys. Res. Commun."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB34|cit34", "first-page": "I", "article-title": "Ro 47-0203, a new endothelin receptor antagonist, reverses chronic vasospasm in experimental subarachnoid hemorrhage", "volume": "88", "author": "ROUZ", "year": "1993", "journal-title": "Circulation"}, {"issue": "Suppl. 5", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "S191", "DOI": "10.1097/00005344-198900135-00053", "article-title": "Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence for multiple endothelin receptor subtypes", "volume": "13", "author": "SPOKES", "year": "1989", "journal-title": "J. Cardiovasc. Pharmacol."}, {"issue": "Suppl. 1", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB36|cit36", "first-page": "169", "article-title": "Nonpeptide endothelin receptor antagonists: cerebrovascular characterization and effects on delayed cerebral vasospasm", "volume": "72", "author": "SULPIZIO", "year": "1994", "journal-title": "Can. J. Physiol. Pharmacol."}, {"key": "10.1111/j.1476-5381.1995.tb13241.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "858", "DOI": "10.1111/j.1476-5381.1992.tb14537.x", "article-title": "Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction", "volume": "107", "author": "SUMNER", "year": "1992", "journal-title": "Br. J. Pharmacol."}, {"issue": "Suppl. 8", "key": "10.1111/j.1476-5381.1995.tb13241.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "S117", "DOI": "10.1097/00005344-199322008-00032", "article-title": "Comparative studies with the endothelin receptor antagonist BQ-123 and PD 142893 indicate at least three endothelin receptors", "volume": "22", "author": "WARNER", "year": "1993", "journal-title": "J. Cardiovasc. Pharmacol."}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1476-5381.1995.tb13241.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 1]], "date-time": "2019-07-01T09:01:08Z", "timestamp": 1561971668000}, "score": 30.009304, "issued": {"date-parts": [[1995, 1]]}, "references-count": 38, "journal-issue": {"published-print": {"date-parts": [[1995, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1111/j.1476-5381.1995.tb13241.x", "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T19:31:21Z", "timestamp": 1574105481125}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1998, 2, 1]], "date-time": "1998-02-01T00:00:00Z", "timestamp": 886291200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1998, 2]]}, "DOI": "10.1016/s0091-3057(97)00442-5", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T23:21:23Z", "timestamp": 1027639283000}, "page": "487-493", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Pharmacological Characterization of PD 152255, a Novel Dimeric Benzimidazole Dopamine D3 Antagonist"], "prefix": "10.1016", "volume": "59", "author": [{"given": "A", "family": "Corbin", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Pharmacology Biochemistry and Behavior"], "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0091-3057(97)00442-5?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0091-3057(97)00442-5?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T05:26:43Z", "timestamp": 1555565203000}, "score": 29.154926, "issued": {"date-parts": [[1998, 2]]}, "references-count": 0, "journal-issue": {"issue": "2"}, "alternative-id": ["S0091-3057(97)00442-5"], "URL": "http://dx.doi.org/10.1016/s0091-3057(97)00442-5", "ISSN": ["0091-3057"], "issn-type": [{"value": "0091-3057", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T06:28:54Z", "timestamp": 1575440934210}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2015, 5, 20]]}, "DOI": "10.1200/jco.2015.33.15_suppl.9597", "type": "journal-article", "created": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T20:39:09Z", "timestamp": 1555706349000}, "page": "9597-9597", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Should all antiemetic guidelines recommend adding a NK1 receptor antagonist (NK1RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK1RA, netupitant, and palonosetron."], "prefix": "10.1200", "volume": "33", "author": [{"given": "Karin", "family": "Jordan", "sequence": "first", "affiliation": [{"name": "University of Halle, Halle, Germany"}]}, {"given": "Richard J.", "family": "Gralla", "sequence": "additional", "affiliation": [{"name": "Albert Einstein College of Medicine - Jacobi Medical Center, Bronx, NY"}]}, {"given": "Giada", "family": "Rizzi", "sequence": "additional", "affiliation": [{"name": "Helsinn Healthcare, Lugano, Switzerland"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.9597", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:47:53Z", "timestamp": 1574887673000}, "score": 29.095589, "issued": {"date-parts": [[2015, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2015.33.15_suppl.9597"], "URL": "http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9597", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T06:14:27Z", "timestamp": 1575440067450}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 5, 1]], "date-time": "2013-05-01T00:00:00Z", "timestamp": 1367366400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacological Reports"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1016/s1734-1140(13)71395-1", "type": "journal-article", "created": {"date-parts": [[2014, 2, 19]], "date-time": "2014-02-19T22:11:24Z", "timestamp": 1392847884000}, "page": "91-92", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Influence of selective A2 adenosine receptor antagonist, DMPX, on the anticonvulsant activity of conventional antiepileptic drugs"], "prefix": "10.1016", "volume": "65", "author": [{"given": "Mariusz", "family": "\u015awi\u0105der", "sequence": "first", "affiliation": []}, {"given": "Jacek", "family": "Por\u0119biak", "sequence": "additional", "affiliation": []}, {"given": "Waldemar A.", "family": "Turski", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Pharmacological Reports"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1734114013713951?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1734114013713951?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 6]], "date-time": "2018-10-06T14:20:21Z", "timestamp": 1538835621000}, "score": 28.924688, "issued": {"date-parts": [[2013, 5]]}, "references-count": 0, "alternative-id": ["S1734114013713951"], "URL": "http://dx.doi.org/10.1016/s1734-1140(13)71395-1", "ISSN": ["1734-1140"], "issn-type": [{"value": "1734-1140", "type": "print"}], "subject": ["Pharmacology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T08:57:24Z", "timestamp": 1574758644907}, "reference-count": 91, "publisher": "Wiley", "issue": "9", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["British Journal of Pharmacology"], "published-print": {"date-parts": [[2016, 5]]}, "DOI": "10.1111/bph.13439", "type": "journal-article", "created": {"date-parts": [[2016, 1, 19]], "date-time": "2016-01-19T20:45:10Z", "timestamp": 1453236310000}, "page": "1452-1464", "source": "Crossref", "is-referenced-by-count": 13, "title": ["Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretionex vivo"], "prefix": "10.1111", "volume": "173", "author": [{"given": "J", "family": "Kong", "sequence": "first", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "J", "family": "Chuddy", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "I A", "family": "Stock", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "P M", "family": "Loria", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "S V", "family": "Straub", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "C", "family": "Vage", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "K O", "family": "Cameron", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "S K", "family": "Bhattacharya", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "K", "family": "Lapham", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "K F", "family": "McClure", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "Y", "family": "Zhang", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}, {"given": "V M", "family": "Jackson", "sequence": "additional", "affiliation": [{"name": "Cardiovascular and Metabolic Diseases Research Unit; Pfizer Worldwide Research and Development; Cambridge MA 01239 USA"}]}], "member": "311", "published-online": {"date-parts": [[2016, 3, 17]]}, "reference": [{"key": "10.1111/bph.13439-BIB0001|bph13439-cit-0002", "doi-asserted-by": "crossref", "first-page": "5744", "DOI": "10.1111/bph.13348", "article-title": "The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors", "volume": "172", "author": "Alexander", "year": "2015", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0002|bph13439-cit-0003", "doi-asserted-by": "crossref", "first-page": "701", "DOI": "10.1210/jc.2002-021161", "article-title": "Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels", "volume": "88", "author": "Arosia", "year": "2003", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0003|bph13439-cit-0004", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1053/gast.2001.22158", "article-title": "Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin.", "volume": "120", "author": "Asakawa", "year": "2001", "journal-title": "Gastroenterol"}, {"key": "10.1111/bph.13439-BIB0004|bph13439-cit-0005", "doi-asserted-by": "crossref", "first-page": "822", "DOI": "10.1124/jpet.102.034827", "article-title": "Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure", "volume": "302", "author": "Banks", "year": "2002", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1111/bph.13439-BIB0005|bph13439-cit-0006", "doi-asserted-by": "crossref", "first-page": "3935", "DOI": "10.1210/jc.2006-2527", "article-title": "Relationships between desacylated and acylated ghrelin and insulin sensitivity in metabolic syndrome", "volume": "92", "author": "Barazzoni", "year": "2007", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0006|bph13439-cit-0007", "doi-asserted-by": "crossref", "first-page": "474", "DOI": "10.1021/ml400473x", "article-title": "Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate", "volume": "5", "author": "Bhattacharya", "year": "2014", "journal-title": "ACS Med Chem Lett"}, {"key": "10.1111/bph.13439-BIB0007|bph13439-cit-0008", "doi-asserted-by": "crossref", "first-page": "325", "DOI": "10.1111/j.1365-2265.2010.03916.x", "article-title": "A practical guide for the stabilization of acylghrelin in human blood collections.", "volume": "74", "author": "Blatnik", "year": "2011", "journal-title": "Clin Endocrinol (Oxf)"}, {"key": "10.1111/bph.13439-BIB0008|bph13439-cit-0009", "doi-asserted-by": "crossref", "first-page": "2447", "DOI": "10.4155/bio.12.248", "article-title": "Prandial ghrelin attenuation provides evidence that des-acyl ghrelin may be an artifact of sample handling in human plasma.", "volume": "4", "author": "Blatnik", "year": "2012", "journal-title": "Bioanalysis"}, {"key": "10.1111/bph.13439-BIB0009|bph13439-cit-0010", "doi-asserted-by": "crossref", "first-page": "5083", "DOI": "10.1210/jcem.86.10.8098", "article-title": "Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans", "volume": "86", "author": "Broglio", "year": "2001", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0010|bph13439-cit-0011", "doi-asserted-by": "crossref", "first-page": "3783", "DOI": "10.1210/jcem.87.8.8749", "article-title": "Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans", "volume": "87", "author": "Broglio", "year": "2002", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0011|bph13439-cit-0012", "doi-asserted-by": "crossref", "first-page": "192", "DOI": "10.1007/BF03345156", "article-title": "Nonacylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans", "volume": "26", "author": "Broglio", "year": "2003a", "journal-title": "J Endocrinol Invest"}, {"key": "10.1111/bph.13439-BIB0012|bph13439-cit-0013", "doi-asserted-by": "crossref", "first-page": "1537", "DOI": "10.1210/jc.2002-021504", "article-title": "The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects", "volume": "88", "author": "Broglio", "year": "2003b", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0013|bph13439-cit-0014", "doi-asserted-by": "crossref", "first-page": "3062", "DOI": "10.1210/jc.2003-031964", "article-title": "Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans", "volume": "89", "author": "Broglio", "year": "2004", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0014|bph13439-cit-0015", "doi-asserted-by": "crossref", "first-page": "G1289", "DOI": "10.1152/ajpgi.00543.2005", "article-title": "Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance", "volume": "290", "author": "Burdyga", "year": "2006", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "10.1111/bph.13439-BIB0015|bph13439-cit-0016", "doi-asserted-by": "crossref", "first-page": "11583", "DOI": "10.1523/JNEUROSCI.2493-08.2008", "article-title": "Cholecystokinin regulates expression of Y2 receptors in vagal afferent neurons serving the stomach", "volume": "28", "author": "Burdyga", "year": "2008", "journal-title": "J Neurosci"}, {"key": "10.1111/bph.13439-BIB0016|bph13439-cit-0017", "doi-asserted-by": "crossref", "first-page": "G63", "DOI": "10.1152/ajpgi.00059.2010", "article-title": "Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype", "volume": "299", "author": "Burdyga", "year": "2010", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "10.1111/bph.13439-BIB0017|bph13439-cit-0018", "doi-asserted-by": "crossref", "first-page": "8671", "DOI": "10.1021/jm5003183", "article-title": "Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists", "volume": "57", "author": "Cameron", "year": "2014", "journal-title": "J Med Chem"}, {"key": "10.1111/bph.13439-BIB0018|bph13439-cit-0019", "doi-asserted-by": "crossref", "first-page": "161", "DOI": "10.1097/00006676-200308000-00009", "article-title": "Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets.", "volume": "27", "author": "Colombo", "year": "2003", "journal-title": "Pancreas"}, {"key": "10.1111/bph.13439-BIB0019|bph13439-cit-0020", "doi-asserted-by": "crossref", "first-page": "158", "DOI": "10.1159/000328968", "article-title": "GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs.", "volume": "94", "author": "Costantini", "year": "2011", "journal-title": "Neuroendocrinology"}, {"key": "10.1111/bph.13439-BIB0020|bph13439-cit-0021", "doi-asserted-by": "crossref", "first-page": "1714", "DOI": "10.2337/diabetes.50.8.1714", "article-title": "A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans", "volume": "50", "author": "Cummings", "year": "2001", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0021|bph13439-cit-0022", "doi-asserted-by": "crossref", "first-page": "1623", "DOI": "10.1056/NEJMoa012908", "article-title": "Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery", "volume": "346", "author": "Cummings", "year": "2002", "journal-title": "N Engl J Med"}, {"key": "10.1111/bph.13439-BIB0022|bph13439-cit-0023", "doi-asserted-by": "crossref", "first-page": "3461", "DOI": "10.1111/bph.12856", "article-title": "Curtis experimental design and analysis and their reporting: New guidance for publication in BJP", "volume": "172", "author": "Curtis", "year": "2015", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0023|bph13439-cit-0024", "doi-asserted-by": "crossref", "first-page": "2555", "DOI": "10.1016/j.febslet.2012.06.034", "article-title": "Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet B-cells", "volume": "586", "author": "Damdindorj", "year": "2012", "journal-title": "FEBS Lett"}, {"key": "10.1111/bph.13439-BIB0024|bph13439-cit-0025", "doi-asserted-by": "crossref", "first-page": "2574", "DOI": "10.1210/jc.2005-1482", "article-title": "Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients", "volume": "91", "author": "Damjanovic", "year": "2006", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0025|bph13439-cit-0026", "doi-asserted-by": "crossref", "first-page": "377", "DOI": "10.5603/EP.2014.0052", "article-title": "Fasting and postprandial acyl and desacyl ghrelin levels in obese and non-obese subjects.", "volume": "65", "author": "Dardzi\u0144ska", "year": "2014", "journal-title": "Endokrynol Pol"}, {"key": "10.1111/bph.13439-BIB0026|bph13439-cit-0027", "doi-asserted-by": "crossref", "first-page": "1120", "DOI": "10.1053/gast.2002.35954", "article-title": "The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats", "volume": "123", "author": "Date", "year": "2002", "journal-title": "Gastroenterology"}, {"key": "10.1111/bph.13439-BIB0027|bph13439-cit-0028", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1016/B978-0-12-381272-8.00016-7", "article-title": "Ghrelin and the vagus nerve", "volume": "514", "author": "Date", "year": "2012", "journal-title": "Methods Enzymol"}, {"key": "10.1111/bph.13439-BIB0028|bph13439-cit-0029", "doi-asserted-by": "crossref", "first-page": "160", "DOI": "10.1016/j.ejphar.2006.03.043", "article-title": "The contractile effect of the ghrelin receptor antagonist, d-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors.", "volume": "537", "author": "Depoortere", "year": "2006", "journal-title": "Eur J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0029|bph13439-cit-0030", "doi-asserted-by": "crossref", "first-page": "3142", "DOI": "10.2337/diabetes.53.12.3142", "article-title": "Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in \u03b2-cells: implication in the glycemic control in rodents", "volume": "53", "author": "Dezaki", "year": "2004", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0030|bph13439-cit-0031", "doi-asserted-by": "crossref", "first-page": "2319", "DOI": "10.2337/db07-0345", "article-title": "Ghrelin uses G\u03b1i2 and activates Kv channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet \u03b2-cells: novel signal transduction of ghrelin", "volume": "56", "author": "Dezaki", "year": "2007", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0031|bph13439-cit-0032", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/j.pharmthera.2008.02.008", "article-title": "Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis", "volume": "118", "author": "Dezaki", "year": "2008", "journal-title": "Pharmacol Ther"}, {"key": "10.1111/bph.13439-BIB0032|bph13439-cit-0033", "doi-asserted-by": "crossref", "first-page": "2315", "DOI": "10.2337/db11-0368", "article-title": "Ghrelin attenuates cAMP-PKA signaling to evoke insulinostatic cascade in islet \u03b2-cells.", "volume": "60", "author": "Dezaki", "year": "2011", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0033|bph13439-cit-0034", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.1530/eje.0.1460241", "article-title": "Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion", "volume": "146", "author": "Egido", "year": "2002", "journal-title": "Eur J Endocrinol"}, {"key": "10.1111/bph.13439-BIB0034|bph13439-cit-0035", "doi-asserted-by": "crossref", "first-page": "5175", "DOI": "10.1210/en.2007-0239", "article-title": "Small molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss", "volume": "148", "author": "Esler", "year": "2007", "journal-title": "Endocrinol"}, {"key": "10.1111/bph.13439-BIB0035|bph13439-cit-0036", "doi-asserted-by": "crossref", "first-page": "5035", "DOI": "10.1210/jc.2004-0363", "article-title": "Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity", "volume": "89", "author": "Gauna", "year": "2004", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0036|bph13439-cit-0037", "doi-asserted-by": "crossref", "first-page": "2988", "DOI": "10.1210/jcem.87.6.8739", "article-title": "The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans", "volume": "87", "author": "Gnanapavan", "year": "2002", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0037|bph13439-cit-0038", "doi-asserted-by": "crossref", "first-page": "3973", "DOI": "10.1113/JP270788", "article-title": "KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelin", "volume": "593", "author": "Grabauskas", "year": "2015", "journal-title": "J Physiol"}, {"key": "10.1111/bph.13439-BIB0038|bph13439-cit-0039", "doi-asserted-by": "crossref", "first-page": "339", "DOI": "10.1159/000088796", "article-title": "A novel growth hormone secretagogue 1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain", "volume": "81", "author": "Halem", "year": "2005", "journal-title": "Neuroendocrinol"}, {"key": "10.1111/bph.13439-BIB0039|bph13439-cit-0040", "doi-asserted-by": "crossref", "first-page": "2201", "DOI": "10.1210/me.2003-0069", "article-title": "High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist", "volume": "17", "author": "Holst", "year": "2003", "journal-title": "Mol Endocrinol"}, {"key": "10.1111/bph.13439-BIB0040|bph13439-cit-0041", "first-page": "1612", "article-title": "Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men", "volume": "16", "author": "Homaee", "year": "2011", "journal-title": "J Res Med Sci"}, {"key": "10.1111/bph.13439-BIB0041|bph13439-cit-0042", "doi-asserted-by": "crossref", "first-page": "439", "DOI": "10.1096/fj.03-0641rev", "article-title": "Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ.", "volume": "18", "author": "Inui", "year": "2004", "journal-title": "FASEB J"}, {"key": "10.1111/bph.13439-BIB0042|bph13439-cit-0043", "first-page": "149", "article-title": "Expression of growth hormone secretatgogue receptor type 1A in visceral vagal and spinal afferent pathways", "volume": "60", "author": "Jia", "year": "2008", "journal-title": "Sheng Li Xue Bao"}, {"key": "10.1111/bph.13439-BIB0043|bph13439-cit-0044", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1016/j.regpep.2004.08.031", "article-title": "Morphological analysis of ghrelin and its receptor distribution in the rat pancreas.", "volume": "126", "author": "Kageyama", "year": "2005", "journal-title": "Regul Pept"}, {"key": "10.1111/bph.13439-BIB0044|bph13439-cit-0045", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1016/S1566-0702(02)00182-0", "article-title": "Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons", "volume": "102", "author": "Kakei", "year": "2002", "journal-title": "Auton Neurosci"}, {"key": "10.1111/bph.13439-BIB0045|bph13439-cit-0046", "first-page": "161", "article-title": "Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action", "volume": "25", "author": "Kapur", "year": "2000", "journal-title": "J Psychiatry Neurosci"}, {"key": "10.1111/bph.13439-BIB0046|bph13439-cit-0047", "doi-asserted-by": "crossref", "first-page": "1577", "DOI": "10.1111/j.1476-5381.2010.00872.x", "article-title": "NC3Rs Reporting Guidelines Working Group", "volume": "160", "author": "Kilkenny", "year": "2010", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0047|bph13439-cit-0048", "doi-asserted-by": "crossref", "first-page": "G1002", "DOI": "10.1152/ajpgi.00313.2001", "article-title": "Characterization of CCK(A) receptor affintity states and Ca(2+) signal transduction in vagal nodose ganglia", "volume": "282", "author": "Lankisch", "year": "2002", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "10.1111/bph.13439-BIB0048|bph13439-cit-0049", "doi-asserted-by": "crossref", "first-page": "4521", "DOI": "10.1210/jc.2004-2537", "article-title": "Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy.", "volume": "90", "author": "Roux", "year": "2005", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0049|bph13439-cit-0050", "doi-asserted-by": "crossref", "first-page": "410", "DOI": "10.1016/j.numecd.2005.02.006", "article-title": "Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations", "volume": "15", "author": "Lucidi", "year": "2005", "journal-title": "Nutr Metab Cardiovasc Dis"}, {"key": "10.1111/bph.13439-BIB0050|bph13439-cit-0051", "doi-asserted-by": "crossref", "first-page": "3189", "DOI": "10.1111/bph.12955", "article-title": "Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP", "volume": "172", "author": "McGrath", "year": "2015", "journal-title": "Br J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0051|bph13439-cit-0052", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.3389/fnins.2013.00087", "article-title": "GHS-R1A constitutive activity and its physiological relevance", "volume": "7", "author": "Mear", "year": "2013", "journal-title": "Front Neurosci"}, {"key": "10.1111/bph.13439-BIB0052|bph13439-cit-0053", "doi-asserted-by": "crossref", "first-page": "2046", "DOI": "10.1016/j.bmcl.2012.01.014", "article-title": "Discovery of a new class of ghrelin receptor antagonists", "volume": "22", "author": "Mihalic", "year": "2012", "journal-title": "Bioorg Med Chem Lett"}, {"key": "10.1111/bph.13439-BIB0053|bph13439-cit-0054", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.2337/diab.45.2.257", "article-title": "Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.", "volume": "45", "author": "Moens", "year": "1996", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0054|bph13439-cit-0055", "first-page": "1612", "article-title": "Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men", "volume": "16", "author": "Moradi", "year": "2011", "journal-title": "J Res Med Sci"}, {"key": "10.1111/bph.13439-BIB0055|bph13439-cit-0056", "first-page": "1", "article-title": "The kinetics of competitive radioligand binding predicted by the law of mass action", "volume": "25", "author": "Motulsky", "year": "1984", "journal-title": "Mol Pharmacol"}, {"key": "10.1111/bph.13439-BIB0056|bph13439-cit-0057", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1007/s00726-012-1355-2", "article-title": "The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonist.", "volume": "44", "author": "Moulin", "year": "2013", "journal-title": "Amino Acids"}, {"key": "10.1111/bph.13439-BIB0057|bph13439-cit-0058", "doi-asserted-by": "crossref", "first-page": "G1376", "DOI": "10.1152/ajpgi.00536.2006", "article-title": "Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents.", "volume": "292", "author": "Page", "year": "2007", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "10.1111/bph.13439-BIB0058|bph13439-cit-0059", "doi-asserted-by": "crossref", "first-page": "5625", "DOI": "10.1210/jc.2002-020776", "article-title": "Plasma ghrelin obesity and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels", "volume": "87", "author": "Pagotto", "year": "2002", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0059|bph13439-cit-0060", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1016/S0143-4160(03)00027-7", "article-title": "Cell-specific Ca(2+) responses in glucose-stimulated single and aggregated beta-cells", "volume": "34", "author": "Pakhtusova", "year": "2003", "journal-title": "Cell Calcium"}, {"key": "10.1111/bph.13439-BIB0060|bph13439-cit-0061", "doi-asserted-by": "crossref", "first-page": "6237", "DOI": "10.1016/j.bmcl.2009.08.076", "article-title": "Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzene sulfonamide ghrelin receptor antagonists", "volume": "19", "author": "Pasternak", "year": "2009", "journal-title": "Bioorg Med Chem Lett"}, {"key": "10.1111/bph.13439-BIB0061|bph13439-cit-0062", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.7150/ijbs.8.108", "article-title": "Identification of ghrelin receptor blocker, d-[Lys3] GHRP-6 as a CXCR4 receptor antagonist", "volume": "8", "author": "Patel", "year": "2012a", "journal-title": "Int J Biol Sci"}, {"key": "10.1111/bph.13439-BIB0062|bph13439-cit-0063", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.7150/ijms.9.51", "article-title": "The GHS-R blocker d-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist.", "volume": "9", "author": "Patel", "year": "2012b", "journal-title": "Int J Med Sci"}, {"key": "10.1111/bph.13439-BIB0063|bph13439-cit-0064", "doi-asserted-by": "crossref", "first-page": "D1098", "DOI": "10.1093/nar/gkt1143", "article-title": "The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands", "volume": "42", "author": "Pawson", "year": "2014", "journal-title": "Nucleic Acids Res"}, {"key": "10.1111/bph.13439-BIB0064|bph13439-cit-0065", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.1097/MAJ.0b013e31824390b9", "article-title": "Ghrelin inhibits inulin release by regulating the expression of inwardly rectifying potassium channel 6.2 in islets", "volume": "343", "author": "Peng", "year": "2012", "journal-title": "Am J Med Sci"}, {"key": "10.1111/bph.13439-BIB0065|bph13439-cit-0066", "doi-asserted-by": "crossref", "first-page": "178", "DOI": "10.1016/j.ejphar.2010.10.042", "article-title": "Pharmacological characterization of the ghrelin receptor antagonist, GSK1614343 in rat RC-4B/C cells natively expressing GHS type 1a receptors.", "volume": "650", "author": "Perdon\u00e0", "year": "2011", "journal-title": "Eur J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0066|bph13439-cit-0067", "doi-asserted-by": "crossref", "first-page": "5623", "DOI": "10.1016/j.bmc.2012.07.018", "article-title": "Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists", "volume": "20", "author": "Puleo", "year": "2012", "journal-title": "Bioorg Med Chem Lett"}, {"key": "10.1111/bph.13439-BIB0067|bph13439-cit-0068", "doi-asserted-by": "crossref", "first-page": "916", "DOI": "10.1210/en.2002-220819", "article-title": "Dose-dependent inhibition by ghrelin of insulin secretion in the mouse", "volume": "144", "author": "Reimer", "year": "2003", "journal-title": "Endocrinology"}, {"key": "10.1111/bph.13439-BIB0068|bph13439-cit-0069", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1016/S0024-3205(00)00911-5", "article-title": "Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds", "volume": "68", "author": "Richelson", "year": "2000", "journal-title": "Life Sci"}, {"key": "10.1111/bph.13439-BIB0069|bph13439-cit-0070", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1038/ijo.2009.40", "article-title": "Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes", "volume": "33", "author": "Rodr\u00edguez", "year": "2009", "journal-title": "Int J Obes (Lond)"}, {"key": "10.1111/bph.13439-BIB0070|bph13439-cit-0071", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1007/s11695-008-9568-x", "article-title": "Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery", "volume": "19", "author": "Roth", "year": "2008", "journal-title": "Obes Surg"}, {"key": "10.1111/bph.13439-BIB0071|bph13439-cit-0072", "doi-asserted-by": "crossref", "first-page": "5202", "DOI": "10.1021/jm070071+", "article-title": "Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity", "volume": "50", "author": "Rudolph", "year": "2007", "journal-title": "J Med Chem"}, {"key": "10.1111/bph.13439-BIB0072|bph13439-cit-0073", "doi-asserted-by": "crossref", "first-page": "1981", "DOI": "10.1002/cmdc.201100285", "article-title": "Azabicyclo[3.1.0]hexane-1-carbohydrazides as potent and selective GHSR1a ligands presenting a specific in\u2005vivo behavior.", "volume": "6", "author": "Sabbatini", "year": "2011", "journal-title": "Chem Med Chem"}, {"key": "10.1111/bph.13439-BIB0073|bph13439-cit-0074", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.1016/S0304-3940(03)00294-5", "article-title": "Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion.", "volume": "342", "author": "Sakata", "year": "2003", "journal-title": "Neurosci Lett"}, {"key": "10.1111/bph.13439-BIB0074|bph13439-cit-0075", "doi-asserted-by": "crossref", "first-page": "945056", "DOI": "10.1155/2010/945056", "article-title": "Ghrelin Cells in the Gastrointestinal Tract", "volume": "2010", "author": "Sakata", "year": "2010", "journal-title": "Intern J Peptides"}, {"key": "10.1111/bph.13439-BIB0075|bph13439-cit-0076", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1016/j.ejphar.2013.06.031", "article-title": "The relationship between gastric motility and nausea: gastric prokinetic agents as treatments.", "volume": "715", "author": "Sanger", "year": "2013", "journal-title": "Eur J Pharmacol"}, {"key": "10.1111/bph.13439-BIB0076|bph13439-cit-0077", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1677/JOE-06-0078", "article-title": "Regulation of GH secretagogue receptor gene expression in the rat nodose ganglion.", "volume": "194", "author": "Sato", "year": "2007", "journal-title": "J Endocrinol"}, {"key": "10.1111/bph.13439-BIB0077|bph13439-cit-0078", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1016/j.neuropharm.2009.06.024", "article-title": "Lean mean fat reducing \u201cghrelin\u201d machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity", "volume": "58", "author": "Schellekens", "year": "2010", "journal-title": "Neuropharm"}, {"key": "10.1111/bph.13439-BIB0078|bph13439-cit-0079", "doi-asserted-by": "crossref", "first-page": "379", "DOI": "10.1016/j.cmet.2006.04.004", "article-title": "Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice", "volume": "3", "author": "Sun", "year": "2006", "journal-title": "Cell Metabol"}, {"key": "10.1111/bph.13439-BIB0079|bph13439-cit-0080", "doi-asserted-by": "crossref", "first-page": "272", "DOI": "10.1111/nmo.12261", "article-title": "Ghrelin increases vagally mediated gastric activity by central sites of action", "volume": "26", "author": "Swartz", "year": "2014", "journal-title": "Neurogastroenterol Motil"}, {"key": "10.1111/bph.13439-BIB0080|bph13439-cit-0081", "doi-asserted-by": "crossref", "first-page": "2145", "DOI": "10.2337/db10-0504", "article-title": "Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans", "volume": "59", "author": "Tong", "year": "2010", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0081|bph13439-cit-0082", "doi-asserted-by": "crossref", "first-page": "653", "DOI": "10.1002/oby.21019", "article-title": "Blunted suppression of acyl-ghrelin in response to fructose ingestion in obese adolescents: the role of insulin resistance", "volume": "23", "author": "Van Name", "year": "2015", "journal-title": "Obesity"}, {"key": "10.1111/bph.13439-BIB0082|bph13439-cit-0083", "doi-asserted-by": "crossref", "first-page": "E1829", "DOI": "10.1152/ajpendo.00682.2006", "article-title": "Clinical pharmacokinetics and metabolic effects", "volume": "292", "author": "Vestergaard", "year": "2007", "journal-title": "Am J Physiol Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0083|bph13439-cit-0084", "doi-asserted-by": "crossref", "first-page": "438", "DOI": "10.1210/jc.2007-2018", "article-title": "Acute effects of ghrelin administration on glucose and lipid metabolism", "volume": "93", "author": "Vestergaard", "year": "2008a", "journal-title": "J Clin Endocinol Metabol"}, {"key": "10.1111/bph.13439-BIB0084|bph13439-cit-0085", "doi-asserted-by": "crossref", "first-page": "3205", "DOI": "10.2337/db08-0025", "article-title": "Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling", "volume": "57", "author": "Vestergaard", "year": "2008b", "journal-title": "Diabetes"}, {"key": "10.1111/bph.13439-BIB0085|bph13439-cit-0086", "doi-asserted-by": "crossref", "first-page": "1300", "DOI": "10.1210/jcem.87.3.8279", "article-title": "Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors", "volume": "87", "author": "Volante", "year": "2002", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0086|bph13439-cit-0087", "doi-asserted-by": "crossref", "first-page": "E695", "DOI": "10.1152/ajpendo.2000.279.3.E695", "article-title": "Effect of CCK pretreatment on the CCK sensitivity of rat polymodal gastric vagal afferent in vitro", "volume": "279", "author": "Wei", "year": "2000", "journal-title": "Am J Physiol Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0087|bph13439-cit-0088", "doi-asserted-by": "crossref", "first-page": "1198", "DOI": "10.1210/jc.2008-0632", "article-title": "Effects of an oral growth hormone secretagogue in older adults", "volume": "94", "author": "White", "year": "2009", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/bph.13439-BIB0088|bph13439-cit-0089", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1016/S0167-0115(02)00067-8", "article-title": "The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas", "volume": "107", "author": "Wierup", "year": "2002", "journal-title": "Regul Pept"}, {"key": "10.1111/bph.13439-BIB0089|bph13439-cit-0090", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1007/s00441-004-1044-x", "article-title": "Ultrastructure of islet ghrelin cells in the human fetus", "volume": "319", "author": "Wierup", "year": "2005", "journal-title": "Cell Tissue Res"}, {"key": "10.1111/bph.13439-BIB0090|bph13439-cit-0091", "doi-asserted-by": "crossref", "first-page": "1859", "DOI": "10.1073/pnas.85.6.1859", "article-title": "[d-Arg1,d-Phe5,d-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3\u00a0T3 cells, inhibits the growth of human small cell lung cancer cells in vitro", "volume": "85", "author": "Woll", "year": "1988", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/bph.13439-BIB0091|bph13439-cit-0092", "doi-asserted-by": "crossref", "first-page": "6334", "DOI": "10.3748/wjg.14.6334", "article-title": "Ghrelin and gastric acid secretion", "volume": "14", "author": "Yakabi", "year": "2008", "journal-title": "World J Gastroenterol"}], "container-title": ["British Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbph.13439", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 3]], "date-time": "2019-09-03T20:48:21Z", "timestamp": 1567543701000}, "score": 28.198307, "subtitle": ["Clinical ghrelin receptor antagonist pharmacology"], "issued": {"date-parts": [[2016, 3, 17]]}, "references-count": 91, "journal-issue": {"published-print": {"date-parts": [[2016, 5]]}, "issue": "9"}, "URL": "http://dx.doi.org/10.1111/bph.13439", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0007-1188"], "issn-type": [{"value": "0007-1188", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T17:24:42Z", "timestamp": 1574097882234}, "reference-count": 26, "publisher": "Elsevier BV", "issue": "2-3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1996, 12, 1]], "date-time": "1996-12-01T00:00:00Z", "timestamp": 849398400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Pharmacology"], "published-print": {"date-parts": [[1996, 12]]}, "DOI": "10.1016/s0014-2999(96)00794-7", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T15:15:26Z", "timestamp": 1027610126000}, "page": "341-347", "source": "Crossref", "is-referenced-by-count": 27, "title": ["In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280"], "prefix": "10.1016", "volume": "318", "author": [{"given": "Alberto F.", "family": "De Arriba", "sequence": "first", "affiliation": []}, {"given": "Luis A.", "family": "G\u00f3mez-Casaj\u00fas", "sequence": "additional", "affiliation": []}, {"given": "Fernando", "family": "Cavalcanti", "sequence": "additional", "affiliation": []}, {"given": "Carme", "family": "Almansa", "sequence": "additional", "affiliation": []}, {"given": "Juli\u00e1n", "family": "Garc\u00eda-Rafanell", "sequence": "additional", "affiliation": []}, {"given": "Javier", "family": "Forn", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Pharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0014299996007947?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0014299996007947?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 27]], "date-time": "2019-04-27T10:54:46Z", "timestamp": 1556362486000}, "score": 27.805094, "issued": {"date-parts": [[1996, 12]]}, "references-count": 26, "journal-issue": {"published-print": {"date-parts": [[1996, 12]]}, "issue": "2-3"}, "alternative-id": ["S0014299996007947"], "URL": "http://dx.doi.org/10.1016/s0014-2999(96)00794-7", "ISSN": ["0014-2999"], "issn-type": [{"value": "0014-2999", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T18:22:37Z", "timestamp": 1575224557278}, "reference-count": 54, "publisher": "American Society for Pharmacology & Experimental Therapeutics (ASPET)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J Pharmacol Exp Ther"], "published-print": {"date-parts": [[2013, 8]]}, "DOI": "10.1124/jpet.113.203554", "type": "journal-article", "created": {"date-parts": [[2013, 5, 18]], "date-time": "2013-05-18T06:26:25Z", "timestamp": 1368858385000}, "page": "241-250", "source": "Crossref", "is-referenced-by-count": 12, "title": ["In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models"], "prefix": "10.1124", "volume": "346", "author": [{"given": "M. T.", "family": "Pulido-Rios", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "McNamara", "sequence": "additional", "affiliation": []}, {"given": "G. P.", "family": "Obedencio", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Ji", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Jaw-Tsai", "sequence": "additional", "affiliation": []}, {"given": "W. J.", "family": "Martin", "sequence": "additional", "affiliation": []}, {"given": "S. S.", "family": "Hegde", "sequence": "additional", "affiliation": []}], "member": "36", "published-online": {"date-parts": [[2013, 5, 17]]}, "reference": [{"key": "2019081411474557000_346.2.241.1", "doi-asserted-by": "crossref", "first-page": "73", "DOI": "10.1111/j.1476-5381.1990.tb12091.x", "article-title": "Evidence for prejunctional M2 muscarinic receptors in pulmonary cholinergic nerves in the rat", "volume": "101", "author": "Aas", "year": "1990", "journal-title": "Br J Pharmacol"}, {"key": "2019081411474557000_346.2.241.2", "DOI": "10.1038/sj.bjp.0706780", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.3", "doi-asserted-by": "crossref", "first-page": "699", "DOI": "10.1152/physrev.1992.72.3.699", "article-title": "Modulation of neurotransmission in airways", "volume": "72", "author": "Barnes", "year": "1992", "journal-title": "Physiol Rev"}, {"key": "2019081411474557000_346.2.241.4", "DOI": "10.1016/0024-3205(93)90310-Y", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.5", "DOI": "10.1378/chest.117.2_suppl.63S", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.6", "first-page": "24S", "article-title": "The role of anticholinergics in chronic obstructive pulmonary disease", "volume": "117", "author": "Barnes", "year": "2004", "journal-title": "Am J Med"}, {"key": "2019081411474557000_346.2.241.7", "DOI": "10.1136/thx.2006.063271", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.8", "DOI": "10.1016/0014-2999(87)90201-9", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.9", "DOI": "10.1183/09059180.00009902", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.10", "DOI": "10.1378/chest.118.5.1294", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.11", "DOI": "10.1183/09031936.02.00269802", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.12", "DOI": "10.1124/jpet.109.152470", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.13", "unstructured": "Celli BR (2004) Pharmacotherapy in chronic obstructive pulmonary disease, Marcel Dekkr Inc, New York.", "DOI": "10.1201/9780203913406", "doi-asserted-by": "crossref"}, {"key": "2019081411474557000_346.2.241.14", "DOI": "10.1016/0024-3205(93)90312-Q", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.15", "first-page": "531", "article-title": "Muscarinic receptor subtypes and smooth muscle function", "volume": "48", "author": "Eglen", "year": "1996", "journal-title": "Pharmacol Rev"}, {"key": "2019081411474557000_346.2.241.16", "first-page": "L101", "article-title": "Expression of muscarinic receptor subtypes and M2-muscarinic inhibition of adenylyl cyclase in lung", "volume": "268", "author": "Emala", "year": "1995", "journal-title": "Am J Physiol"}, {"key": "2019081411474557000_346.2.241.17", "DOI": "10.1124/jpet.109.151639", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.18", "first-page": "309", "article-title": "Characterization of muscarinic receptors in human, guinea pig and rat lung", "volume": "250", "author": "Gies", "year": "1989", "journal-title": "J Pharmacol Exp Ther"}, {"key": "2019081411474557000_346.2.241.19", "DOI": "10.1378/chest.96.5.984", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.20", "first-page": "899", "article-title": "Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping", "volume": "45", "author": "Haddad", "year": "1994", "journal-title": "Mol Pharmacol"}, {"key": "2019081411474557000_346.2.241.21", "DOI": "10.1038/sj.bjp.0702573", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.22", "doi-asserted-by": "crossref", "first-page": "1974", "DOI": "10.1378/chest.128.4.1974", "article-title": "Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma", "volume": "128", "author": "Hansel", "year": "2005", "journal-title": "Chest"}, {"key": "2019081411474557000_346.2.241.23", "DOI": "10.1016/S0024-3205(98)00586-4", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.24", "first-page": "L304", "article-title": "Pre- and postjunctional muscarinic receptors in canine bronchi", "volume": "259", "author": "Janssen", "year": "1990", "journal-title": "Am J Physiol"}, {"key": "2019081411474557000_346.2.241.25", "first-page": "1845", "article-title": "Principles of nebulizer-delivered drug therapy for asthma", "volume": "46", "author": "Johnson", "year": "1989", "journal-title": "Am J Hosp Pharm"}, {"key": "2019081411474557000_346.2.241.26", "DOI": "10.1136/adc.88.10.911", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.27", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.2147/COPD.S4802", "article-title": "Tiotropium HandiHaler in the treatment of COPD: a safety review", "volume": "4", "author": "Kesten", "year": "2009", "journal-title": "Int J Chron Obstruct Pulmon Dis"}, {"key": "2019081411474557000_346.2.241.28", "DOI": "10.1378/chest.130.6.1695", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.29", "DOI": "10.1016/j.clinthera.2005.04.006", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.30", "DOI": "10.1002/bdd.280", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.31", "doi-asserted-by": "crossref", "first-page": "1136", "DOI": "10.1164/ajrccm.161.4.9903044", "article-title": "Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease", "volume": "161", "author": "Littner", "year": "2000", "journal-title": "Am J Respir Crit Care Med"}, {"key": "2019081411474557000_346.2.241.32", "DOI": "10.1183/09031936.06.00126005", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.33", "first-page": "1031", "article-title": "Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD", "volume": "6", "author": "Maesen", "year": "1993", "journal-title": "Eur Respir J"}, {"key": "2019081411474557000_346.2.241.34", "first-page": "1506", "article-title": "Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)", "volume": "8", "author": "Maesen", "year": "1995", "journal-title": "Eur Respir J"}, {"key": "2019081411474557000_346.2.241.35", "DOI": "10.1016/j.vascn.2010.05.016", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.36", "DOI": "10.1016/j.ejphar.2008.12.043", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.37", "doi-asserted-by": "crossref", "first-page": "575", "DOI": "10.2147/COPD.S3530", "article-title": "Safety, tolerability and risk benefit analysis of tiotropium in COPD", "volume": "3", "author": "Oba", "year": "2008", "journal-title": "Int J Chron Obstruct Pulmon Dis"}, {"key": "2019081411474557000_346.2.241.38", "DOI": "10.1254/jphs.10311FP", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.39", "unstructured": "Potgieter P, Hopkins A, Liu P, Quinn C, Amburgey C, and Moran E (2012) A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD. European Respiratory Society Annual Congress 2012. 9-5-2012. 9-1-9012."}, {"key": "2019081411474557000_346.2.241.40", "DOI": "10.7326/0003-4819-147-9-200711060-00008", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.41", "DOI": "10.1164/rccm.200703-456SO", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.42", "DOI": "10.1016/j.archoralbio.2007.07.012", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.43", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1111/j.1600-0773.1994.tb01070.x", "article-title": "The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice", "volume": "74", "author": "S\u00e1nchez", "year": "1994", "journal-title": "Pharmacol Toxicol"}, {"key": "2019081411474557000_346.2.241.44", "doi-asserted-by": "crossref", "first-page": "L1125", "DOI": "10.1152/ajplung.00084.2002", "article-title": "Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus", "volume": "283", "author": "Sarria", "year": "2002", "journal-title": "Am J Physiol Lung Cell Mol Physiol"}, {"key": "2019081411474557000_346.2.241.45", "unstructured": "Schulz H Muhle H (2000) Respiration, in The laboratory rat ( Krinke G , ed) pp 323\u2013344, Academic Press, Waltham, MA.", "DOI": "10.1016/B978-012426400-7/50055-8", "doi-asserted-by": "crossref"}, {"key": "2019081411474557000_346.2.241.46", "first-page": "A4553", "article-title": "In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator (Abstract)", "volume": "179", "author": "Steinfeld", "year": "2009", "journal-title": "Am J Respir Crit Care Med"}, {"key": "2019081411474557000_346.2.241.47", "DOI": "10.1056/NEJMoa0805800", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.48", "unstructured": "(2003) Tiotropium NDA-21-395. FDA CDER Tiotropium NDA-21-395. Pharmacol Rev 021395 (S-000 Part 01): https://www.pharmapendium.com/fda.do?drugName=Tiotropium+Bromide+Monohydrate Accessed April 10, 2013."}, {"key": "2019081411474557000_346.2.241.49", "DOI": "10.1136/thorax.55.4.289", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.50", "DOI": "10.1183/09031936.02.00238002", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.51", "DOI": "10.1164/rccm.201204-0596PP", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.52", "DOI": "10.1183/09031936.00082507", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.53", "DOI": "10.1183/09031936.02.00238702", "doi-asserted-by": "publisher"}, {"key": "2019081411474557000_346.2.241.54", "DOI": "10.1016/j.pupt.2010.04.005", "doi-asserted-by": "publisher"}], "container-title": ["Journal of Pharmacology and Experimental Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1124/jpet.113.203554", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 14]], "date-time": "2019-08-14T18:50:55Z", "timestamp": 1565808655000}, "score": 27.720787, "issued": {"date-parts": [[2013, 5, 17]]}, "references-count": 54, "journal-issue": {"published-online": {"date-parts": [[2013, 7, 17]]}, "published-print": {"date-parts": [[2013, 8]]}, "issue": "2"}, "alternative-id": ["10.1124/jpet.113.203554"], "URL": "http://dx.doi.org/10.1124/jpet.113.203554", "relation": {"cites": []}, "ISSN": ["0022-3565", "1521-0103"], "issn-type": [{"value": "0022-3565", "type": "print"}, {"value": "1521-0103", "type": "electronic"}], "subject": ["Molecular Medicine", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:31:03Z", "timestamp": 1574811063094}, "reference-count": 36, "publisher": "Springer Science and Business Media LLC", "issue": "11", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 6, 22]], "date-time": "2016-06-22T00:00:00Z", "timestamp": 1466553600000}, "delay-in-days": 0, "content-version": "unspecified"}], "funder": [{"DOI": "10.13039/100008129", "name": "Helsinn", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Support Care Cancer"], "published-print": {"date-parts": [[2016, 11]]}, "DOI": "10.1007/s00520-016-3304-1", "type": "journal-article", "created": {"date-parts": [[2016, 6, 23]], "date-time": "2016-06-23T11:04:51Z", "timestamp": 1466679891000}, "page": "4617-4625", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens"], "prefix": "10.1007", "volume": "24", "author": [{"given": "Karin", "family": "Jordan", "sequence": "first", "affiliation": []}, {"given": "Richard", "family": "Gralla", "sequence": "additional", "affiliation": []}, {"given": "Giada", "family": "Rizzi", "sequence": "additional", "affiliation": []}, {"given": "Kimia", "family": "Kashef", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 6, 22]]}, "reference": [{"issue": "1", "key": "3304_CR1", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1200/JCO.1997.15.1.103", "volume": "15", "author": "PJ Hesketh", "year": "1997", "unstructured": "Hesketh PJ, Kris MG, Grunberg SM, et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "3304_CR2", "doi-asserted-by": "crossref", "first-page": "381", "DOI": "10.1200/JCO.2015.64.3635", "volume": "34", "author": "PJ Hesketh", "year": "2016", "unstructured": "Hesketh PJ, Bohlke K, Lyman GH, et al. (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381\u2013386", "journal-title": "J Clin Oncol"}, {"key": "3304_CR3", "unstructured": "MASCC/ESMO Antiemetic Guideline (2016). Available from: http://www.mascc.org/assets/Guidelines-tools/mascc_antiemetic_guidelines_english_2016_v.1.1.pdf"}, {"key": "3304_CR4", "unstructured": "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2016). Antiemesis Version 2. Available from: http://www.nccn.org"}, {"issue": "3", "key": "3304_CR5", "first-page": "191", "volume": "4", "author": "PJ Hesketh", "year": "1999", "unstructured": "Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4(3):191\u2013196", "journal-title": "Oncologist"}, {"key": "3304_CR6", "doi-asserted-by": "crossref", "first-page": "810", "DOI": "10.1056/NEJM199003223221204", "volume": "322", "author": "LX Cubeddu", "year": "1990", "unstructured": "Cubeddu LX, Hoffmann I, Guenmayor NT, Finn AL (1990) Efficacy of ondansetron and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810\u2013816", "journal-title": "N Engl J Med"}, {"key": "3304_CR7", "first-page": "487", "volume": "58", "author": "DM Gershenson", "year": "1981", "unstructured": "Gershenson DM, Wharton JT, Herson J, et al. (1981) Single-agent cisplatinum therapy for advanced ovarian cancer. Obstet Gynecol 58:487", "journal-title": "Obstet Gynecol"}, {"key": "3304_CR8", "doi-asserted-by": "crossref", "first-page": "80", "DOI": "10.1007/s00520-004-0718-y", "volume": "13", "author": "SM Grunberg", "year": "2005", "unstructured": "Grunberg SM, Osoba D, Hesketh PJ, et al. (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014an update. Support Care Cancer 13:80\u201384", "journal-title": "Support Care Cancer"}, {"issue": "6", "key": "3304_CR9", "doi-asserted-by": "crossref", "first-page": "1081", "DOI": "10.1093/annonc/mdv138", "volume": "26", "author": "K Jordan", "year": "2015", "unstructured": "Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV). Ann Oncol 26(6):1081\u20131090", "journal-title": "Ann Oncol"}, {"issue": "5", "key": "3304_CR10", "doi-asserted-by": "crossref", "first-page": "531", "DOI": "10.3109/02841869409083931", "volume": "33", "author": "A Bois Du", "year": "1994", "unstructured": "Du Bois A, Vach W, Thomssen C, et al. (1994) Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. Acta Oncol 33(5):531\u2013535", "journal-title": "Acta Oncol"}, {"key": "3304_CR11", "unstructured": "PARAPLATIN\u00ae (carboplatin aqueous solution) INJECTION [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. Revised Apr 2015"}, {"key": "3304_CR12", "doi-asserted-by": "crossref", "first-page": "718", "DOI": "10.1200/JCO.1992.10.5.718", "volume": "10", "author": "K Swenerton", "year": "1992", "unstructured": "Swenerton K, Jeffrey J, Stuart G, et al. (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 10:718\u2013726", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "3304_CR13", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1159/000227253", "volume": "50", "author": "EV Hannigan", "year": "1993", "unstructured": "Hannigan EV, Green S, Alberts DS, et al. (1993) Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50(2):2\u20139", "journal-title": "Oncology"}, {"key": "3304_CR14", "doi-asserted-by": "crossref", "first-page": "859", "DOI": "10.1038/bjc.2013.400", "volume": "109", "author": "M Tanioka", "year": "2013", "unstructured": "Tanioka M, Kitao A, Matsumoto K, et al. (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70\u00a0years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859\u2013865", "journal-title": "Br J Cancer"}, {"key": "3304_CR15", "doi-asserted-by": "crossref", "first-page": "259", "DOI": "10.1016/j.lungcan.2014.03.017", "volume": "84", "author": "Y Ito", "year": "2014", "unstructured": "Ito Y, Karayama M, Inui N, et al. (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259\u2013264", "journal-title": "Lung Cancer"}, {"key": "3304_CR16", "author": "H Yahata", "year": "2015", "unstructured": "Yahata H, Kobayashi H, Sonoda K, et al. (2015) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. doi: 10.1007/s10147-015-0928-y", "journal-title": "Int J Clin Oncol", "DOI": "10.1007/s10147-015-0928-y", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "3304_CR17", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1016/S1359-6349(09)72092-0", "volume": "7", "author": "R Gralla", "year": "2009", "unstructured": "Gralla R, Rapoport B, Brown C, et al. (2009) Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers. Eur J Cancer 7(3):23\u201324 (abstr 57LBA)", "journal-title": "Eur J Cancer"}, {"key": "3304_CR18", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1007/s00520-009-0680-9", "volume": "18", "author": "BL Rapoport", "year": "2010", "unstructured": "Rapoport BL, Jordan K, Boice JA, et al. (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423\u2013431", "journal-title": "Support Care Cancer"}, {"key": "3304_CR19", "author": "PJ Hesketh", "year": "2016", "unstructured": "Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing chemotherapy induced nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer doi: 10.1002/cncr.30054", "journal-title": "Cancer", "DOI": "10.1002/cncr.30054", "doi-asserted-by": "publisher"}, {"key": "3304_CR20", "doi-asserted-by": "crossref", "first-page": "26", "DOI": "10.1016/j.ejphar.2013.08.049", "volume": "722", "author": "C Rojas", "year": "2014", "unstructured": "Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26\u201337", "journal-title": "Eur J Pharmacol"}, {"issue": "1\u20133", "key": "3304_CR21", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1016/j.ejphar.2012.05.037", "volume": "689", "author": "M Stathis", "year": "2012", "unstructured": "Stathis M, Pietra C, Rojas C, Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689(1\u20133):25\u201330", "journal-title": "Eur J Pharmacol"}, {"issue": "4", "key": "3304_CR22", "doi-asserted-by": "crossref", "first-page": "158", "DOI": "10.1016/S1359-6349(07)70675-4", "volume": "5", "author": "J Morganroth", "year": "2009", "unstructured": "Morganroth J, Parisi S, Moresino C, Thorn M, Cullen MT (2009) High dose palonosetron does not alter ECG parameters, including QTc interval in healthy subjects: results of a dose response, double blind, randomized parallel E14 study of palonosetron vs moxifloxacin or placebo. Eur J Cancer 5(4):158\u2013159 (abstr 1156)", "journal-title": "Eur J Cancer"}, {"key": "3304_CR23", "doi-asserted-by": "crossref", "first-page": "1435", "DOI": "10.1007/s00520-011-1226-5", "volume": "20", "author": "G Gonullu", "year": "2012", "unstructured": "Gonullu G, Demircan S, Demirag MK, et al. (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20:1435\u20131439", "journal-title": "Support Care Cancer"}, {"key": "3304_CR24", "doi-asserted-by": "crossref", "first-page": "2343", "DOI": "10.1007/s00520-011-1348-9", "volume": "20", "author": "C Yavas", "year": "2012", "unstructured": "Yavas C, Dogan U, Yavas G, et al. (2012) Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 20:2343\u20132347", "journal-title": "Support Care Cancer"}, {"key": "3304_CR25", "first-page": "462", "volume": "16", "author": "U Dogan", "year": "2012", "unstructured": "Dogan U, Yavas G, Tekinalp M, et al. (2012) Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur Rev Med Pharmacol Sci 16:462\u2013468", "journal-title": "Eur Rev Med Pharmacol Sci"}, {"issue": "1", "key": "3304_CR26", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.1093/annonc/mdq600", "volume": "22", "author": "P Feyer", "year": "2011", "unstructured": "Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30\u201338", "journal-title": "Ann Oncol"}, {"issue": "10", "key": "3304_CR27", "doi-asserted-by": "crossref", "first-page": "1570", "DOI": "10.1093/annonc/mdg417", "volume": "14", "author": "R Gralla", "year": "2003", "unstructured": "Gralla R, Lichinitser M, Van Der Vegt S, et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570\u20131577", "journal-title": "Ann Oncol"}, {"issue": "2", "key": "3304_CR28", "doi-asserted-by": "crossref", "first-page": "115", "DOI": "10.1016/S1470-2045(08)70313-9", "volume": "10", "author": "M Saito", "year": "2009", "unstructured": "Saito M, Aogi K, Sekine I, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial. Lancet Oncol 10(2):115\u2013124", "journal-title": "Lancet Oncol"}, {"issue": "9", "key": "3304_CR29", "doi-asserted-by": "crossref", "first-page": "1441", "DOI": "10.1093/annonc/mdl137", "volume": "17", "author": "MS Aapro", "year": "2006", "unstructured": "Aapro MS, Grunberg SM, Manikhas GM, et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441\u20131449", "journal-title": "Ann Oncol"}, {"issue": "8", "key": "3304_CR30", "doi-asserted-by": "crossref", "first-page": "2637", "DOI": "10.1007/s00221-014-4017-7", "volume": "232", "author": "AG Thomas", "year": "2014", "unstructured": "Thomas AG, Stathis M, Rojas C, Slusher BS (2014) Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res 232(8):2637\u20132644", "journal-title": "Exp Brain Res"}, {"key": "3304_CR31", "doi-asserted-by": "crossref", "first-page": "1340", "DOI": "10.1093/annonc/mdu110", "volume": "25", "author": "PJ Hesketh", "year": "2014", "unstructured": "Hesketh PJ, Rossi G, Rizzi G, et al. (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346", "journal-title": "Ann Oncol"}, {"key": "3304_CR32", "doi-asserted-by": "crossref", "first-page": "1328", "DOI": "10.1093/annonc/mdu101", "volume": "25", "author": "M Aapro", "year": "2014", "unstructured": "Aapro M, Rugo H, Rossi G, et al. (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333", "journal-title": "Ann Oncol"}, {"key": "3304_CR33", "doi-asserted-by": "crossref", "first-page": "1333", "DOI": "10.1093/annonc/mdu096", "volume": "25", "author": "RJ Gralla", "year": "2014", "unstructured": "Gralla RJ, Bosnjak SM, Hontsa A, et al. (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339", "journal-title": "Ann Oncol"}, {"key": "3304_CR34", "doi-asserted-by": "crossref", "first-page": "4112", "DOI": "10.1200/JCO.2003.01.095", "volume": "21", "author": "PJ Hesketh", "year": "2003", "unstructured": "Hesketh PJ, Grunberg S, Gralla R, et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 study group. J Clin Oncol 21:4112\u20134119", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "3304_CR35", "doi-asserted-by": "crossref", "first-page": "3090", "DOI": "10.1002/cncr.11433", "volume": "97", "author": "S Poli-Bigelli", "year": "2003", "unstructured": "Poli-Bigelli S, Rodrigues-Peretra J, Carides A, et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098", "journal-title": "Cancer"}, {"issue": "6", "key": "3304_CR36", "doi-asserted-by": "crossref", "first-page": "1000", "DOI": "10.1093/annonc/mdl019", "volume": "17", "author": "HJ Schmoll", "year": "2006", "unstructured": "Schmoll HJ, Aapro M, Poli-Bigelli S, et al. (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000\u20131006", "journal-title": "Ann Oncol"}], "container-title": ["Supportive Care in Cancer"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s00520-016-3304-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s00520-016-3304-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s00520-016-3304-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T16:55:10Z", "timestamp": 1498323310000}, "score": 27.69263, "issued": {"date-parts": [[2016, 6, 22]]}, "references-count": 36, "journal-issue": {"published-print": {"date-parts": [[2016, 11]]}, "issue": "11"}, "alternative-id": ["3304"], "URL": "http://dx.doi.org/10.1007/s00520-016-3304-1", "relation": {"cites": []}, "ISSN": ["0941-4355", "1433-7339"], "issn-type": [{"value": "0941-4355", "type": "print"}, {"value": "1433-7339", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}